UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A new era in the treatment of atopic dermatitis

British journal of dermatology (1951), 2019-10, Vol.181 (4), p.658-658

Lebwohl, M.

2019

Volltextzugriff (PDF)

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

British journal of dermatology (1951), 2020-03, Vol.182 (3), p.605-617

2020

Volltextzugriff (PDF)

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis

Journal of the European Academy of Dermatology and Venereology, 2022-06, Vol.36 (6), p.797-806

2022

Volltextzugriff (PDF)

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

British journal of dermatology (1951), 2013-04, Vol.168 (4), p.844-854

2013

Volltextzugriff (PDF)

Do we need a patient satisfaction score?

British journal of dermatology (1951), 2014-03, Vol.170 (3), p.494-495

Lebwohl, M.

2014

Volltextzugriff (PDF)

Itch: an under‐recognized problem in psoriasis

Journal of the European Academy of Dermatology and Venereology, 2019-08, Vol.33 (8), p.1465-1476

2019

Volltextzugriff (PDF)

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

British journal of dermatology (1951), 2021-12, Vol.185 (6), p.1135-1145

2021

Volltextzugriff (PDF)

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study

Journal of the European Academy of Dermatology and Venereology, 2020-02, Vol.34 (2), p.301-309

2020

Volltextzugriff (PDF)

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3

British journal of dermatology (1951), 2018-08, Vol.179 (2), p.320-328

2018

Volltextzugriff (PDF)

Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials

British journal of dermatology (1951), 2020-04, Vol.182 (4), p.880-888

2020

Volltextzugriff (PDF)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

British journal of dermatology (1951), 2022-03, Vol.186 (3), p.466-475

2022

Volltextzugriff (PDF)

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey

Journal of the European Academy of Dermatology and Venereology, 2015-10, Vol.29 (10), p.2002-2010

2015

Volltextzugriff (PDF)

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis

Journal of the European Academy of Dermatology and Venereology, 2021-02, Vol.35 (S1), p.35-41

2021

Volltextzugriff (PDF)

Dupilumab as a treatment for generalized idiopathic pruritus: a report of two cases

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.1494-1495

2020

Volltextzugriff (PDF)

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

British journal of dermatology (1951), 2015-05, Vol.172 (5), p.1371-1383

2015

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies

Journal of the American Academy of Dermatology, 2009-04, Vol.60 (4), p.643-659

2009

Volltextzugriff (PDF)

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

British journal of dermatology (1951), 2021-11, Vol.185 (5), p.935-944

2021

Volltextzugriff (PDF)

Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis

Journal of the European Academy of Dermatology and Venereology, 2021-02, Vol.35 (S1), p.3-4

2021

Volltextzugriff (PDF)

Actinic keratosis: epidemiology and progression to squamous cell carcinoma

British journal of dermatology (1951), 2003-11, Vol.149 (s66), p.31-33

Lebwohl, M.

2003

Volltextzugriff (PDF)

AB0544 EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND reSURFACE 2

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.1304-1305

2021

Volltextzugriff (PDF)

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials

British journal of dermatology (1951), 2019-02, Vol.180 (2), p.306-314

2019

Volltextzugriff (PDF)

Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

Journal of the European Academy of Dermatology and Venereology, 2021-04, Vol.35 (4), p.919-927

2021

Volltextzugriff (PDF)

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

Journal of the European Academy of Dermatology and Venereology, 2021-01, Vol.35 (1), p.135-142

2021

Volltextzugriff (PDF)

Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study

Journal of the European Academy of Dermatology and Venereology, 2021-05, Vol.35 (5), p.1152-1160

2021

Volltextzugriff (PDF)

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

British journal of dermatology (1951), 2021-04, Vol.184 (4), p.640-651

2021

Volltextzugriff (PDF)

1 – 25 von 1.098

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(932)
Mit Volltextzugriff
(857)

Publikationsform

Sprache

Englisch
(1.071)
Französisch
(26)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(13)

Menü

Weitere Dienste

Einstellungen

A new era in the treatment of atopic dermatitis

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

Do we need a patient satisfaction score?

Itch: an under‐recognized problem in psoriasis

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3

Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey

Addressing challenges associated with long‐term topical treatment and benefits of proactive management in patients with psoriasis

Dupilumab as a treatment for generalized idiopathic pruritus: a report of two cases

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis

Actinic keratosis: epidemiology and progression to squamous cell carcinoma

AB0544 EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND reSURFACE 2

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials

Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)

Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

Suchergebnisse filtern